Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of quadrivalent HPV vaccine in Chinese girls and young women
2023-001144-29Phase 3
- Sponsor
- Merck & Co.
- Start
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of qHPV vaccine in human papillomavirus infection, Cervical Cancer (CC), cervical intraepithelial neoplasia (CIN) and 1 more (2 arms), sponsored by Merck & Co. Primary endpoint: Geometric mean titers for serum anti-HPV types 6, 11, 16, and 18.
02
Drugs
qHPV vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)cervical intraepithelial neoplasia (CIN)cervical adenocarcinoma
Beyond the preview
Go deeper on 2023-001144-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-001144-29.